Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Slavinorm is a peptide-based bioregulator and geroprotector derived from calf aorta extract. It is primarily indicated for the treatment of obliterating atherosclerosis of the lower extremity arteries (peripheral arterial disease). The drug exerts antiatherogenic and antiischemic effects by optimizing the blood-lipid profile—specifically increasing high-density lipoproteins (HDL) and decreasing other cholesterol fractions—and improving microcirculation through the optimization of vascular endothelial function. Clinical studies have demonstrated its efficacy in increasing pain-free walking distance (PFWD) and improving the ankle-brachial index (ABI) in patients with stage IIb atherosclerosis. It is administered via intramuscular injection and has also shown potential antiischemic effects in models of acute myocardial infarction by reducing necrotic zones and post-occlusion arrhythmias.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Slavinorm.